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Abstract: Childhood-onset growth hormone deficiency (CO-GHD) is an endocrine condition 
associated with a broad range of health issues from childhood through to adulthood, which 
requires particular attention during the transition period from adolescence to young adulthood. 
There is uncertainty in the clinical practice of the management of CO-GHD during transition 
regarding the clinical assessment and management of individual patients during and after 
transition to obtain optimal follow-up and improved health outcomes. Despite the availability 
of clinical guidelines providing the framework for transition of young adults with CO-GHD, 
there remains substantial variation in approaching transitional care among pediatric and adult 
services. A well-structured and coordinated transitional plan with clear communication and 
direct collaboration between pediatric and adult health care to ensure optimal management of 
adolescents with CO-GHD during transition is needed.
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Introduction
Transition is a planned process that aims to address the wider set of medical, psycho-
logical and educational requirements of young adults with chronic conditions as they 
move from pediatric to adult health services.1 Increased survival of children with com-
plex health conditions has led to growing attention on the importance of the quality of 
services provided for adolescents during transition. Childhood-onset growth hormone 
deficiency (CO-GHD) is one of a number of complex endocrine conditions that may 
have an impact throughout life, starting in childhood and continuing into adulthood. 
Transition of patients with CO-GHD that have been treated with recombinant human 
growth hormone (rhGH) during childhood is a challenging phase for health care 
providers. This phase occurs in CO-GHD from mid-late teens until approximately 
6 or 7 years after final height has been reached.2 This is a critical period for maximiz-
ing bone mass and muscle strength, which are important determinants for the risk of 
fractures related to osteoporosis occurring later in life.3 The presented data largely sup-
port the positive role of rhGH therapy during the transition period of adolescence and 
beyond.4,5 The effects of CO-GHD and the benefits of rhGH therapy during transition 
have been previously described in several studies.6–10 Although there are numerous 
publications that have discussed transition in general with some specifically discussing 
CO-GHD,2,6,11 a number of unanswered issues still remain.
Current practice during transition
Several clinical practice guidelines have described the theoretical framework for the 
transition of adolescents with CO-GHD.2,12–15 However, in the clinical practice setting, 
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both adult and pediatric endocrinologists lack consistency 
when managing the adolescent patients with CO-GHD during 
transition. The clinical experience in Scotland highlighted 
various areas of uncertainty in clinical practice:16 the best 
method of evaluating the hypothalamic–pituitary axis, 
identification of patients to test, determining which test to 
use for diagnosing persistent growth hormone deficiency 
(GHD), identifying which patients would most benefit from 
continued rhGH treatment and methods of ascertaining if 
patients should continue treatment. In addition, it is unclear 
with whom the responsibility for the biochemical reevalu-
ation of GHD lies, the pediatric endocrinologist or adult 
endocrinologist who will decide whether to continue rhGH 
therapy into adulthood and the involvement of patients and 
family in making the decision and management plan. Practice 
varies across the UK, particularly in cases when no organic 
cause for GHD is identified.16–18
The current guidelines classify CO-GHD according to 
the likelihood of persistent GHD.2,12,13 A previous history of 
organic disease, deficits in two or more additional pituitary 
hormones,19,20 hypothalamic–pituitary structural abnormali-
ties as well as tumour-related organic GHD are strong pre-
dictors of persistent GHD.21–24 Patients who are considered 
having a high probability of persistent GHD may not require 
their growth hormone (GH) status to be reevaluated and 
should continue rhGH without interruption. Those who are 
less likely to have persistent GHD should undergo reevalu-
ation of the GH axis before resuming rhGH replacement 
therapy.2 Although there are clearly stated criteria under both 
categories, other factors such as clinical observations and 
development of symptoms could influence the decision of 
how the patients are categorized and managed. In addition, 
there is no clear reevaluation pathway for those who exhibit 
a discordant GH and IGF-1 pattern.
The timing of retesting is another issue. According to 
guidelines, the decision when to reassess depends largely on 
attainment of adult height as defined (height velocity ,2 cm/
year). The recommended washout interval between stopping 
rhGH and retesting is from 1 to 3 months,2 although there 
are no existing data on the optimal shortest interval without 
rhGH for retesting reliability and health parameters. There is 
some evidence, however, that the longer interval and delay in 
reinstituting rhGH may have an impact on optimizing skeletal 
outcomes in these subjects,25 as well as other parameters, such 
as cardiovascular and lipid profiles.26 Moreover, a longer 
period off rhGH during reevaluation may increase the risk 
of losing patients to follow-up.27
GH stimulation tests are used to reevaluate GH levels 
taking into account the appropriate cutoff limits with various 
assay measurements.28,29 The insulin tolerance test (ITT) is 
considered the gold standard to reevaluate secretion of GH in 
these patients. Assuming adequate hypoglycemia is achieved, 
this test can distinguish GH deficiency from the sufficient GH 
secretion that is linked with obesity and normal aging. This 
test, however, is contraindicated in patients with epilepsy or 
heart disease. Given this precaution, the only alternative reli-
able stimulation tests that can be used are glucagon/growth 
hormone-releasing hormone (GHRH)+arginine, taking into 
account appropriate cutoff limits.2
Cutoff levels for peak GH responses to stimulation tests 
during the transition period are still arbitrary; studies use a 
peak GH cutoff ,5.1 µg/L,23 ,6.1 µg/L30 or ,5.6 µg/L.31 The 
European Society for Pediatric Endocrinology recommended 
a cutoff ,5 µg/L, using the ITT as an appropriate criterion 
for GH replacement during transition.2 In CO-GHD where 
persistent GHD is highly likely, confirmation of persistent 
GHD can be made by a low IGF-I level alone (,-2 SD for 
age and gender) measured after at least 1 month off rhGH 
therapy, without the need for any further stimulation testing.5 
Figure 1 illustrates the current proposal workup of diagnos-
ing and reevaluating CO-GHD patients during transition,2 
highlighting the areas of uncertainty.
It is currently recommended to restart rhGH at a low 
dose (0.2–0.3 mg/day) and then titrate to attain IGF-1 levels 
that fall into the upper half of the normal range. The dose of 
rhGH is then adjusted during the transition to adult treatment, 
with young females receiving oral estrogen requiring higher 
rhGH doses. IGF-1 should be measured during dose adjust-
ment at 1–2-month intervals and also a minimum of once a 
year during therapy in order for it to be kept at an age- and 
sex-appropriate level.2
Benefits of rhGH during transition
The broader benefits of rhGH for optimizing other health aspects 
during childhood and the period of the transition to adulthood 
are becoming more widely recognized (Figure 2).32,33
Bone and fracture risk
There is currently conflicting evidence on whether CO-GHD 
contributes to low bone mass and an increased risk of fracture 
in adulthood,34–36 although mechanisms and the pathophysi-
ology of bone mass reduction are still far from fully under-
stood. Indeed, many factors such as gender, height, age at 
onset, body composition, gonadal status, GHD severity and 
assessment methods may all contribute to inconsistent data 
on bone mass in patients with CO-GHD. Studies suggest 
that CO-GHD results in developmental bone mass deficits 
both at the time of diagnosis37,38 and at retesting when final 
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height has been reached.39 Reinstitution of rhGH replace-
ment beyond the attainment of final height in young adults 
who have persistent CO-GHD has been reported to have a 
positive effect on bone density with a net benefit change in 
bone mineral density (BMD) of lumber spine ranging from 
3% to 6% after 1 year35 or 2 years.4,40–42 On the other hand, 
some studies did not find any change in BMD up to 2 years 
after either discontinuation of rhGH43 or after reinstitut-
ing rhGH replacement therapy after final height has been 
reached.34,44 In addition, there are scarce data on the link 
between bone density and fracture risk in adolescents and 
young adults with CO-GHD that were observed in adults 
with GHD and hypopituitarism.45,46 Previous studies have 
reported increased fracture risk in adults with CO-GHD47,48 
and only in women with CO-GHD in another study,49 while 
another study did not find any difference in the risk of frac-
ture in adolescents with CO-GHD compared with that in the 
normal population.50 Therefore, there is no clear evidence 
that the CO-GHD results in low bone mass or increases the 
risk of fracture.
Body composition and muscle strength
During transition after withdrawal of childhood rhGH 
replacement therapy, several but not all studies have showed 
a significant decrease in lean mass (LM; -8%) parallel 
by increased fat mass (FM; 10%–17%) in patients with 
CO-GHD who were diagnosed with persistent GHD and had 
stopped rhGH for at least 2 years.4,34,51,52 Restarting rhGH 
therapy resulted in a notable improvement in body composi-
tion, with LM increasing by 14% and FM being reduced by 
Figure 1 Schema for assessing the GH/IGF-1 axis during the transition period.
Notes: Areas of uncertainty: 1) who should have their GH axis reevaluated and who is responsible, pediatric or adult endocrinologist? 2) what is the optimal duration for 
washout? 3) what are the criteria for low and high risk of persistent GHD? 4) those with a high risk of persistence GHD, do they still require reevaluation or should they 
continue GH therapy? 5) what is the GH peak cutoff? 6) when and where to follow up those who no longer have GHD? 7) monitoring and the outcome of second reevaluation 
at age 25 and 8) what if patient declines GH therapy? Adapted with permission from the European Journal of Endocrinology, from Clayton PE, Cuneo RC, Juul A, Monson JP, 
Shalet SM, Tauber M. European Society of Paediatric Endocrinology. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. 
Eur J Endocrinol. 2005;152(2):165–170. Copyright 2018. Permission conveyed through Copyright Clearance Center, Inc.2
Abbreviations: GH, growth hormone; GHD, growth hormone deficiency; MRI, magnetic resonance imaging; PBM, peak bone mass.
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7% over 2 years of therapy.4,41 In terms of muscle strength, 
previous studies have reported a lower maximum isotonic 
strength in young adults with CO-GHD, as measured by 
hand grip force,53,54 but the effects on muscle strength in 
adolescents with CO-GHD during transition still remain to 
be completely elucidated.55 There are some suggestions that 
reduced muscle mass was the cause of diminished muscle 
strength in GHD, as opposed to a reduction in contractile 
function.56 Furthermore, it has been proposed that CO-GHD 
may initially result in a reduction in muscle mass and force, 
which would ultimately have an impact on bone density and 
geometry.57 However, little research has been carried out 
into the relationship between muscle and bone strength in 
adult GHD patients,58 and there has been no existing study 
targeting CO-GHD in children and adolescents.
Cardiovascular risks and glucose 
homeostasis
It has been reported in some studies that adolescents with 
CO-GHD have adverse lipid profiles after they discontinue 
rhGH treatment upon reaching final height,26,51,52,59 but not 
all studies.41,44,51,60 These parameters have been found to 
improve after restarting rhGH replacement therapy.26,61–63 
In addition, it has been noted that the longer the rhGH ther-
apy is discontinued, the more abnormal the lipid profiles.64 
It is possible that the alterations in lipid profiles observed 
when rhGH is discontinued may be partly explained by the 
short-term effects of rhGH therapy and therefore could not 
be analyzed independently of treatment duration during 
childhood.65 Studies of adults with GHD provided evidence 
for this assumption, revealing that only long periods of rhGH 
therapy (in the range of 5–10 years) were associated with 
improved lipid profiles in adult GHD patients.66,67 Further 
research is required to confirm this hypothesis in CO-GHD. 
In addition to aberrations in lipid profiles, direct impacts of 
CO-GHD on cardiac structure and function were reported 
in some echocardiographic studies. A study observed a 
decrease in all cardiac dimensions of adolescents with 
CO-GHD after withdrawal of rhGH during the transition 
period, when reinstituting rhGH results in a significant 
increase in left ventricular (LV) mass index and exercises 
capacity after 12–24 months63,68 with improvement in 
endothelial function within the first 6 months of restarting 
rhGH.69
Regarding glucose homeostasis parameters, children with 
CO-GHD have been reported to be more insulin sensitive at 
the time of initial diagnosis70 and after rhGH is withdrawn 
when they reach final height.51,71 However, adults with GHD 
have been found to have an increased likelihood of insulin 
resistance,67,72 but this is not the case for adolescents.63 It is 
Figure 2 Impact of GH replacement therapy during transition of CO-GHD.
Notes: *Duration of GH replacement variable. ↑, increase; ↓, decrease and ↔, no significant changes or different.
Abbreviations: GH, growth hormone; CO-GHD, childhood-onset growth hormone deficiency; CVS, cardiovascular system; QoL, quality of life.
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not clear whether changes in glucose homeostasis in these 
subjects can be attributed to GHD itself, body composition 
and adiposity or both, with no clear evidence for an increased 
risk of developing diabetes.73,74
Quality of life (QoL)
GH/IGF-1 axis may play a role in normal brain structure, cog-
nitive function, psychology and thereby QoL.75,76 A study of 
children with isolated-GHD revealed a significant reduction 
in white matter, corpus callosum and neural volumes.77 Given 
these findings, several clinical studies have been carried out 
to evaluate the effects of discontinuing and subsequently 
resuming rhGH treatment with regard to QoL elements in 
young adults with CO-GHD during transition from child-
hood to adulthood.
Some studies reported no changes in QoL in patients with 
CO-GHD, when measured at the time they discontinued rhGH 
after reaching final height and after 2 years remeasured while 
either off or resuming rhGH therapy.33,41,44 Another study 
further reported no impairment in QoL in short-stature ado-
lescents and children with GHD and without GHD,78 which 
indicates that other unknown confounders could influence 
QoL other than height and GH levels.79 On the other hand, 
other studies have stated that adolescent CO-GHD patients 
who had been treated with rhGH and then discontinued 
therapy after attaining height suffered from some cognitive 
and psychological impairment, particularly in domains of 
attention, memory, energy drive, emotional reactions and 
social isolation.80,81 These measures significantly improved 
when rhGH treatment was restarted. An inverse relationship 
has been reported between QoL and rhGH therapy duration; 
a longer period without rhGH was associated with a poorer 
QoL, whereas restarting rhGH treatment had a significantly 
positive effect on health-related QoL aspects.64 There is also 
some evidence that discontinuing rhGH treatment resulted 
in decreased QoL within 6 months, which was improved 
in 3–6 months after recommencing rhGH therapy.81,82 
Although individuals with GHD treated with rhGH reported 
having a higher self-esteem compared with short-stature and 
normal-stature children,83,84 the replacement of rhGH in adult 
CO-GHD patients resulted in less QoL improvement than in 
those with adult-onset GHD,33 even after undergoing rhGH 
therapy for long-term periods of 4–10 years.85
Challenges for future
The need for an appropriate transition service is increas-
ingly recognized within health care systems. Generally, the 
purpose of transition is to offer adolescent patients continu-
ity of care and promote mental and physical health through 
the exchange of information among health care workers in 
order to optimize their health and QoL aspects.11 Although 
the existing guidelines have theoretically described how 
to reevaluate CO-GHD during transition, there is no clear 
pathway about how to organize and deliver transitional 
care from pediatric to adult services. Much of the transition 
literature has focused on the risk of untreated GHD during 
transition in terms of health and QoL outcomes; however, 
none of the studies have identified a clear transition plan, 
before and after reevaluation follow-up. Several studies have 
highlighted the risks of adolescents who drop out specialist 
endocrine care during the transition to adulthood care. The 
Scottish audit demonstrated 21% of patients stopped rhGH 
replacement without comprehensive reevaluation and 18% 
of patients did not attend follow-up while on treatment and 
never returned to endocrine clinics. This study has also 
highlighted issues about the follow-up of patients who no 
longer have GHD and particularly those patients with per-
sistent GHD who have chosen not to resume adult rhGH 
treatment.16 In another endocrine setting, transitional care 
was evaluated in patients with congenital adrenal hyper-
plasia reporting that 50% of the whole cohort were lost to 
follow-up following transfer to adult care,86 with only 10% 
of the expected numbers still attending the adult endocrine 
service in another study.87
The current transition of endocrine conditions including 
GHD has been reported to be of suboptimal quality in young 
adults with endocrine conditions.88,89 Such studies provide an 
insight into actual practice barriers and potential solutions 
for successful transition. The readiness of the patients and 
their caregivers, appropriate environmental setting and local 
resources were described as factors, which interfere with 
the precise format of the service and successful transition. 
There are various expert-based recommendations on how 
to improve transition and provide quality services for other 
chronic endocrine diseases, for example, type 1 diabetes 
mellitus,90 turner syndrome,91 and hypogonadism92. Other 
reports suggest some strategies for successful transition 
including standardized referral systems and establishment 
of transition centers to ensure that the needs of young adults 
with CO-GHD are being met.93,94 In addition, for optimizing 
transitional care, it was recommended that pediatric and 
adult endocrinologists collaborate and share information 
while understanding that some overlap and a joint transi-
tion service would optimize the follow-up and transfer of 
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adolescents,94 although there are lack of data about patient 
attendance and follow-up after transition. The existing 
theoretical generic models have demonstrated structured 
processes of transitioning adolescents from pediatric to 
adult care.95,96 However, there appears to be clear difficulties 
in the feasibility of implementation of the all processes at 
every center and/or for every individual. Using the model 
designed by Gleeson et al, application of this model faces 
several challenges for effective transition of adolescents 
with CO-GHD as outlined in Table 1. In addition to the 
above highlighted areas of uncertainty in the schema of 
reevaluation and management of adolescents with CO-GHD, 
the model does not address issues concerning the readiness 
of patients and their caregiver to transition, transition clinic 
visits and frequency of appointments. The arrangement and 
duration to get the first adult care appointment, together with 
aspects to ensure the continuity of care, are also important 
factors. Therefore, there is a growing need to further review 
the current practices and develop more specific models for 
better planning and promoting the continuity of care during 
and after transition.
Conclusion
Transition is a concept of a multidisciplinary approach that 
ensures continuity of health care while adolescents with 
complex health conditions are transferred from pediatric 
care to adult care. There is some evidence that recommenc-
ing rhGH treatment in CO-GHD during transition results in 
not only improved growth and bone health but also a better 
prognosis for metabolic and cardiovascular risks in the long 
term. Further studies are required on the current practice of 
assessing and managing CO-GHD, as well as research into 
the long-term follow-up of patients who have been confirmed 
to have persistent CO-GHD and continuous monitoring for 
optimizing somatic and psychological outcomes in patients. 
The major challenge during this stage, however, is appropri-
ately identifying candidates for adult GH therapy. The current 
guidelines need to be reviewed, addressing areas of uncertainly 
Table 1 Transition process from pediatric to adult care
Generic model* Application for CO-GHD Challenges
Pediatric 
care
Young person and family 
work in partnership with 
health care professionals 
and have early discussions 
about transition planning
•	 Reassessment of etiology and disease-specific 
management
•	 Reassessment of the GH treatment regimen
•	 Assessment of readiness and preference of 
patients and their care giver
•	 Who, when, where and how to reevaluate GH 
axis
•	 Referral to transition clinic
Transition 
care
Young person grows in 
knowledge, confidence and 
independence in managing 
their health care and other 
aspects of life
•	 MDT team include pediatric endocrinologist, 
adult endocrinologist, specialist nurses, 
access to psychologists and social workers
•	 Discuss transfer plan
•	 Family support – education and ability to self-
manage
•	 Restarting rhGH in those confirmed with 
persistent GHD
•	 Clear plan for those who have GHD only 
patients to keep follow-up and reassessment 
in 2-years time
•	 Clinical resources
•	 Patients and care giver need to be involved in the 
management
•	 Transition clinic visit and frequency of 
appointments
•	 Follow-up for those who no longer have GHD
Transfer Young person is currently 
stable in terms of their 
condition and life, ready to 
transfer and demonstrates 
increasing autonomy in his 
or her health care
Plan first adult care appointment •	 Arrangement and duration to get first adult care 
appointment
•	 To ensure the continuity of care
Adult care Young person is fully 
autonomous in health care 
and well on his or her way 
to achieving his or her adult 
potential
Full adult care •	 Regular follow-up and rhGH replacement therapy
•	 Monitoring health and QoL aspects
Follow-up Reevaluation at completion of somatic growth 
(approximately 25–30 years)
•	 The outcome of reevaluation in young adulthood
•	 Clinical decision
Note: *Model designed by Gleeson et al 2012.88
Abbreviations: CO-GHD, childhood-onset growth hormone deficiency; GH, growth hormone; MDT, multidisciplinary team; rhGH, recombinant human growth hormone; 
QoL, quality of life.
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as evidenced by variation in clinical practice. Hence, clearly a 
structured transition protocol is a vital key to establish the best 
practice of transitioning adolescents with CO-GHD.
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